Dr Agarwals Health Care Ltd
Incorporated in 2010,[1]Dr. Agarwal’s Health Care offers a wide array of eye care services, which include cataract and refractive surgeries, consultations, diagnoses, and non-surgical treatments. Additionally, they provide optical products, contact lenses, accessories, and pharmaceutical items related to eye care. [2]
- Market Cap ₹ 15,954 Cr.
 - Current Price ₹ 505
 - High / Low ₹ 568 / 327
 - Stock P/E 304
 - Book Value ₹ 61.8
 - Dividend Yield 0.00 %
 - ROCE 5.94 %
 - ROE 1.31 %
 - Face Value ₹ 1.00
 
Pros
- Company has delivered good profit growth of 20.9% CAGR over last 5 years
 
Cons
- Stock is trading at 8.39 times its book value
 - Though the company is reporting repeated profits, it is not paying out dividend
 - Company has low interest coverage ratio.
 - Company has a low return on equity of 3.29% over last 3 years.
 
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 202 | 248 | 232 | 362 | 598 | 835 | 1,044 | 1,160 | |
| 186 | 202 | 199 | 275 | 436 | 611 | 795 | 886 | |
| Operating Profit | 16 | 46 | 33 | 86 | 162 | 224 | 249 | 274 | 
| OPM % | 8% | 19% | 14% | 24% | 27% | 27% | 24% | 24% | 
| 5 | 9 | 4 | 10 | -12 | 38 | 40 | 52 | |
| Interest | 20 | 42 | 34 | 38 | 64 | 88 | 94 | 81 | 
| Depreciation | 21 | 49 | 55 | 59 | 92 | 129 | 156 | 174 | 
| Profit before tax | -20 | -36 | -52 | -1 | -6 | 45 | 39 | 71 | 
| Tax % | -0% | -0% | 4% | 55% | -641% | 47% | 43% | |
| -20 | -36 | -54 | -1 | 32 | 24 | 22 | 49 | |
| EPS in Rs | 0.69 | 1.56 | ||||||
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 33% | 
| 3 Years: | 42% | 
| TTM: | 24% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 21% | 
| 3 Years: | 152% | 
| TTM: | 140% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| 1 Year: | % | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 1% | 
| 3 Years: | 3% | 
| Last Year: | 1% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 8 | 9 | 32 | 32 | 
| Reserves | 290 | 248 | 194 | 192 | 554 | 1,218 | 1,902 | 1,924 | 
| 135 | 142 | 161 | 252 | 590 | 661 | 568 | 589 | |
| 60 | 200 | 281 | 242 | 236 | 298 | 335 | 299 | |
| Total Liabilities | 492 | 596 | 643 | 692 | 1,388 | 2,187 | 2,837 | 2,844 | 
| 99 | 322 | 387 | 367 | 907 | 1,302 | 1,591 | 1,769 | |
| CWIP | 1 | 3 | 11 | 2 | 35 | 9 | 18 | 5 | 
| Investments | 238 | 146 | 121 | 147 | 187 | 629 | 729 | 670 | 
| 154 | 124 | 124 | 176 | 258 | 248 | 498 | 400 | |
| Total Assets | 492 | 596 | 643 | 692 | 1,388 | 2,187 | 2,837 | 2,844 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 40 | 46 | 78 | 153 | 222 | 208 | ||
| -37 | -26 | -98 | -436 | -818 | -577 | ||
| -60 | -21 | 40 | 316 | 570 | 374 | ||
| Net Cash Flow | -56 | -1 | 20 | 33 | -26 | 5 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 46 | 39 | 31 | 24 | 22 | 25 | 
| Inventory Days | 138 | 159 | 147 | 149 | 119 | 135 | 174 | 
| Days Payable | 330 | 427 | 608 | 456 | 354 | 383 | 375 | 
| Cash Conversion Cycle | -147 | -222 | -422 | -276 | -210 | -226 | -176 | 
| Working Capital Days | 5 | -37 | -43 | -54 | -88 | -79 | -55 | 
| ROCE % | 1% | -5% | 9% | 10% | 8% | 6% | 
Documents
Announcements
- 
        
          Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
          
            31 Oct - Audio recording of Oct 31, 2025 analyst/earnings call for Q2/H1 FY2025-26 results posted.
 - Announcement under Regulation 30 (LODR)-Investor Presentation 31 Oct
 - 
        
          Announcement under Regulation 30 (LODR)-Monitoring Agency Report
          
            30 Oct - ICRA monitoring report (Sep 30, 2025): INR300 crore IPO proceeds, INR42.964 crore unutilized, no deviations.
 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 30 Oct
 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2025 30 Oct
 
Concalls
- 
      Oct 2025TranscriptNotesPPT
 - 
      Sep 2025Transcript PPT
 - 
      Aug 2025Transcript PPT REC
 - 
      Jun 2025Transcript PPT
 - 
      Feb 2025Transcript PPT REC
 
Largest Eyecare Service Provider[1]
Dr. Agarwal is India's largest eye care service chain with a 25% market share. It is the largest company by revenue in FY23, with more than two times the revenue from operations of the second-largest eye care service chain in the country.